Table 2 Effects of risk factors on metastasis following operation by univariate analysis

 Others^a

15 (4.89%)

1

 Adenocarcinoma

151 (49.19%)

1.20 (0.52, 2.75)

0.68

 Squamous carcinoma

141 (45.93%)

0.95 (0.41, 2.23)

0.91

 I

9 (2.93%)

1

 II

59 (19.22%)

2.00 (0.60, 6.63)

0.26

 III

40 (13.03%)

0.95 (0.26, 3.46)

0.94

 NA

199 (64.82%)

1.74 (0.55, 5.51)

0.34

 No

207 (67.43%)

1

 Yes

100 (32.57%)

0.69 (0.47, 1.01)

0.06

 IB

60 (19.54%)

1

 IIA

16 (5.21%)

1.01 (0.37, 2.78)

0.99

 IIB

125 (40.72%)

1.90 (1.10, 3.50)

0.02

 IIIA

90 (29.32%)

3.52 (1.97, 6.27)

< 0.01

 IIIB

16 (5.21%)

4.39 (1.96, 9.81)

< 0.01

 Taxane+Platinum

129 (42.02%)

1

 Gemcitabine+Platinum

65 (21.17%)

1.08 (0.67, 1.72)

0.76

 Pemetrexed+Platinum

108 (35.18%)

1.07 (0.73, 1.57)

0.72

 < 4

100 (32.57%)

1

 ≥ 4

207 (67.43%)

0.71 (0.50, 1.02)

0.06

 No

163 (53.09%)

1

 Yes

144 (46.91%)

0.93 (0.66, 1.31)

0.69

 No

282 (91.86%)

1

 Yes

25 (8.14%)

1.47 (0.81, 2.67)

0.21

 No

277 (90.23%)

1

 Yes

30 (9.77%)

1.34 (0.77, 2.35)

0.30

 No rhG-CSF

61 (19.87%)

1

 rhG-CSF

246 (80.13%)

2.30 (1.36, 3.88)

< 0.01

 0

61 (19.87%)

1

 ≤ 500

96 (31.27%)

2.67 (1.52, 4.70)

< 0.01

 500–1000

85 (27.69%)

2.24 (1.25, 4.02)

< 0.01

 1000–1500

32 (10.42%)

1.63 (0.80, 3.35)

0.18

 > 1500

33 (10.75%)

2.29 (1.15, 4.57)

0.02

 0

67 (21.82%)

1

 < 15

71 (23.13%)

1.60 (0.91, 2.82)

0.10

 15–60

89 (28.99%)

1.76 (1.01, 3.06)

0.04

 60–200

38 (12.38%)

2.45 (1.30, 4.60)

0.01

 ≥ 200

42 (13.68%)

3.89 (2.12, 7.12)

< 0.01